507 related articles for article (PubMed ID: 24650691)
1. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
6. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Enea M; Bruno R; Bronte F; Capursi V; Cicchetti A; Colombo GL; Di Marco V; Gasbarrini A; Craxì A;
Hepatology; 2012 Sep; 56(3):850-60. PubMed ID: 22454336
[TBL] [Abstract][Full Text] [Related]
10. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
Cortesi PA; Ciaccio A; Rota M; Lim JK; De Salvia S; Okolicsanyi S; Vinci M; Belli LS; Mantovani LG; Strazzabosco M
J Viral Hepat; 2015 Feb; 22(2):175-83. PubMed ID: 25040391
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Blázquez-Pérez A; San Miguel R; Mar J
Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
[TBL] [Abstract][Full Text] [Related]
14. [Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
Guglieri-López B; Ventura-Cerdá JM; Gómez-Álvarez S; Climente-Martí M
Enferm Infecc Microbiol Clin; 2015 May; 33(5):331-6. PubMed ID: 25128462
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Craxì A; Cammà C;
Hepatology; 2014 May; 59(5):1692-705. PubMed ID: 24691835
[TBL] [Abstract][Full Text] [Related]
17. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
20. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
